Cencora (NYSE:COR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

Cencora COR has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...

Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is updating its model following Cencora’s results and ...

As the crypto with the ninth-highest market cap, DOGE is far from in the doghouse, but it's still a risky play.

**NM signifies a non meaningful value. A dash signifies the data is not available.

COR opened at $253.88 on Wednesday. The firm has a market cap of $49.23 billion, a P/E ratio of 36.11, a P/E/G ratio of 1.31 and a beta of 0.51. Cencora has a 12 month low of $214.77 and a 12 ...

Shares of Cencora Inc. COR slid 2.56% to $254.00 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to 5,599.30 and ...

With a market cap of $50.5 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions provider specializing in pharmaceutical distribution and related services.

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $262.56 in the previous session.

We recently published a list of 10 Stocks With At Least $30 Million In Insider Sales Recently. In this article, we are going to take a look at where Cencora, Inc. (NYSE:COR) stands against other ...

The FDA’s latest draft guidance on accelerated approval for new drugs, “Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics,” is a game-changer for biopharmaceutical ...